COST Action B22 on
"Drug development for parasitic diseases"
2003-2007
History of the Proposal
The presentation of this new COST Action is made on behalf of scientists representing several COST countries members who met through COST Action B9 "Chemotherapy of Protozoal Infections" that is due to end in September 2002. A Report of the activities of COST B9 including a list of papers published by MC members in 1996-2002 is available. Click here to download the report as a PDF file
The aims of the previous
COST Action B9 were to develop links between experts in EU
countries. The Working Groups on Drugs, on Chemistry and on Drug
Screening sought to identify active research groups, organise
Workshops and Expert Meetings on cross-disciplinary themes,
establish collaborative links between academic groups, critically
review biochemical targets, explore contacts with the
pharmaceutical industry, and engender a European identity in
anti-protozoal drug discovery. The new COST proposal will exploit
the identified expertise and link groups in academia and industry
together along the established drug development structure "from
molecules to man". The proposed COST Action is structured into
Working Groups on Genomics and Target identification, Target
Characterisation and Drug Design, Drug Evaluation, Pre-clinical
Development and Drug Resistance. Extensive contacts between
academic scientists and SME and large pharmaceutical companies in
Europe that have re-engaged in anti-parasitic drug development
will be developed bringing scientists from industry into the
activities. Hence, the new COST will differ from COST B9 in aims,
structure and extent of activities.
Back
to Index